Zyvox® (linezolid), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections

被引：0
作者：
Brickner, Steven J. [1 ]
Barbachyn, Michael R. [2 ]
Hutchinson, Douglas K. [3 ]
Manninen, Peter R. [4 ]
机构：
[1] Pfizer Inc, Antibacterials Chem, Groton New London Labs, Groton, CT 06340 USA
[2] Pfizer Inc, Dept Chem, Ann Arbor, MI 48105 USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
[4] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 233卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
257-MEDI
引用
收藏
页码：607 / 607
页数：1
相关论文
共 50 条
[41]   New antibiotics for treatment of serious infections due to anti biotic-resistant Gram-positive cocci [J].
Bassetti, M ;
Melica, G ;
Di Biagio, A ;
Righi, E ;
Rosso, R ;
Bassetti, D .
REVIEWS IN MEDICAL MICROBIOLOGY, 2004, 15 (03) :109-117
[42]   New antibiotic class effectively treats challenging gram-positive infections [J].
不详 .
FORMULARY, 1999, 34 (11) :967-967
[43]   Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections [J].
Brade K.D. ;
Rybak J.M. ;
Rybak M.J. .
Infectious Diseases and Therapy, 2016, 5 (1) :1-15
[44]   Comparative study on safety of linezolid and vancomycin in the treatment of infants and neonates for Gram-positive bacterial infections [J].
Shibata, Yuichi ;
Yamagishi, Yuka ;
Mikamo, Hiroshige ;
Kato, Hideo ;
Nishiyama, Naoya ;
Asai, Nobuhiro ;
Koizumi, Yusuke ;
Matsuura, Katsuhiko ;
Suematsu, Hiroyuki ;
Hagihara, Mao .
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (09) :695-701
[45]   Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia [J].
Smith, PF ;
Birmingham, MC ;
Noskin, GA ;
Meagher, AK ;
Forrest, A ;
Rayner, CR ;
Schentag, JJ .
ANNALS OF ONCOLOGY, 2003, 14 (05) :795-801
[46]   Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis [J].
Yang, Minjie ;
Zhang, Jing ;
Chen, Yuancheng ;
Liang, Xiaoyu ;
Guo, Yan ;
Yu, Jicheng ;
Zhu, Demei ;
Zhang, Yingyuan .
FUTURE MICROBIOLOGY, 2017, 12 (01) :39-50
[47]   Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain [J].
Grau, S. ;
Aguado, J. M. ;
Antonio, J. Mateu-De ;
Gonzalez, P. ;
Del Castillo, A. .
JOURNAL OF CHEMOTHERAPY, 2007, 19 (04) :398-409
[48]   Health economic issues in the treatment of drug-resistant serious Gram-positive infections [J].
Nathwani, Dilip .
JOURNAL OF INFECTION, 2009, 59 :S40-S50
[49]   Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance [J].
Segreti, J .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 :29-35
[50]   Efficacy and tolerability of linezolid therapy in the treatment of orthopedic implant infections caused by gram-positive multiresistant cocci [J].
Jover-Diaz, F. ;
Talents, A. ;
Alcala-Santaella, R. ;
Cuadrado, J. M. ;
Olmedo, N. ;
Gazquez, C. .
REVISTA CLINICA ESPANOLA, 2010, 210 (03) :145-146
12345